No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VYGR Voyager Therapeutics
- 8.510
- -0.290-3.30%
Close Jun 14 16:00 ET
- 8.450
- -0.060-0.71%
Post 17:25 ET
462.89MMarket Cap-50058P/E (TTM)
8.770High8.450Low378.15KVolume8.650Open8.800Pre Close3.22MTurnover1.03%Turnover Ratio2.87P/E (Static)54.39MShares14.07052wk High1.36P/B311.79MFloat Cap6.06052wk Low--Dividend TTM36.64MShs Float31.910Historical High--Div YieldTTM3.64%Amplitude2.460Historical Low8.527Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company
Express News | HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $30 Price Target
Voyager Therapeutics: A Buy Rating on the Back of Strategic Advancements and a Promising Alzheimer's Candidate
Express News | Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
Express News | Voyager Aims for Initial Tau Pet Imaging Data by Second Half of 2026
Comments
$Voyager Therapeutics(VYGR.US$ Benzinga· 2 mins ago
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
Voyager Therapeutics Says First Participants Dosed In Single Ascending Dose Trial of VY-TAU01 For Treatment Of Alzheimer's Disease
$Voyager Therapeutics(VYGR.US$ Voyager Therapeutics To Present Translational Data For IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials At ASGCT 27th Annual Meeting
$Voyager Therapeutics(VYGR.US$ Voyager Therapeutics And Neurocrine Biosciences Have Selected Lead Development Candidate In GBA1 Gene Therapy Program For Potential Treatment Of Parkinson's Disease And Other GBA1-mediated Diseases. Triggers 3 million milestone payment
$Voyager Therapeutics(VYGR.US$ buy the low
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg